Early-onset Familial Hypoaldosteronism

Key Findings

Finding 1 — CYP11B2 loss of function causes isolated aldosterone deficiency

Biallelic inactivating mutations in CYP11B2 (chr8q24.3, encoding the mitochondrial cytochrome P450 aldosterone synthase) cause an isolated defect in aldosterone biosynthesis. The two clinical forms, CMO I (OMIM 203400) and CMO II (OMIM 610600), are distinguished by residual terminal enzyme activity. A critical quantitative principle is that enzymatic activity must generally fall below ~1% of normal before aldosterone biosynthesis is measurably impaired, reflecting substantial functional reserve in the pathway. Documented pathogenic variants include p.Gly452Arg, p.Thr185Ile, the compound R173K+E198D+V386A allele, and in-frame deletion of Arg173.

"Pathogenic variants in CYP11B2 result in corticosterone methyloxidase type I deficiency (CMO I), an orphan condition with a potentially lethal electrolyte imbalance in infancy." — PMID: 41229259

"Many mutations have been documented in each of these genes; in general enzymatic activity must be reduced to <1% of normal for aldosterone biosynthesis to be impaired." — PMID: 15134805

"The first, corticosterone methyloxidase type I (CMO I or type 1 deficiency), is characterized by no detectable aldosterone secretion, a low or normal secretion of the steroid 18OHB" — PMID: 9814506

Finding 2 — Clinical presentation: neonatal/infantile salt wasting with a high-renin, low-aldosterone profile

Patients present in the neonatal period or early infancy with failure to thrive, feeding problems, recurrent vomiting and dehydration, severe hyponatremia, hyperkalemia, and metabolic acidosis. The laboratory hallmark is markedly elevated plasma renin activity with low (CMO I) or inappropriately normal (CMO II) plasma aldosterone. Because cortisol synthesis is unaffected, this is an isolated mineralocorticoid defect. The pathognomonic biochemical signature of CMO II is an elevated 18-hydroxycorticosterone/aldosterone ratio.

"We studied an infant with failure to thrive and persistent hyponatremia despite oral sodium supplementation. Initial analyses revealed highly elevated plasma renin but normal values of plasma aldosterone." — PMID: 22931312

"diagnosed initially in the neonatal period because of severe hyponatremia, hyperkalemia, metabolic acidosis, and failure to thrive" — PMID: 41229259

"presented with failure to thrive and feeding problems at age 6 weeks. Important laboratory findings were low plasma sodium and elevated potassium and renin." — PMID: 9838244

Finding 3 — Diagnosis by steroid profiling and CYP11B2 sequencing; treatment with fludrocortisone is highly effective and often discontinuable

Biochemical diagnosis rests on multisteroid analysis demonstrating the pathognomonic elevation of the 18-hydroxycorticosterone/aldosterone ratio (CMO II) together with elevated precursors (11-deoxycorticosterone [DOC], corticosterone, 18-OHDOC). Molecular confirmation is by CYP11B2 sequencing. Mineralocorticoid replacement with fludrocortisone (± sodium chloride supplementation in infancy) corrects the electrolyte disturbance and produces catch-up growth. Because distal-tubular aldosterone responsiveness matures with age and dietary salt intake rises, treatment can frequently be discontinued in later childhood without deterioration — in one documented case, stopped at age 9 years without relapse.

"revealing a pathognomonic pattern with a highly elevated ratio of 18-OH-corticosterone to aldosterone" — PMID: 22931312

"Treatment with fludrocortisone resulted in catch-up growth. Discontinuation of treatment at the age of 9 years was later possible without any clinical or biochemical deterioration." — PMID: 22931312

"secrete increased amounts of the steroid precursors DOC, corticosterone, and 18OHDOC, and are subject to salt wasting and poor growth" — PMID: 9814506

Finding 4 — Pathophysiology and differential diagnosis

The isolated nature of the defect (normal cortisol, no hyperpigmentation) is the central clinical discriminator from aldosterone-resistance disorders and from CAH. ASD must be separated from pseudohypoaldosteronism type 1 (PHA1) — a resistance disorder in which aldosterone is HIGH — and from 21-hydroxylase deficiency CAH (low cortisol, ambiguous genitalia, hyperpigmentation).

"Aldosterone synthase deficiency (ASD), which is caused by a genetic defect in CYP11B2, involves a deficiency in aldosterone alone." — PMID: 41905953

"ASD must also be differentiated from another disease, pseudohypoaldosteronism type 1 (PHA1), which involves resistance to aldosterone. PHA1a is caused by a heterozygous defect in NR3C2, which encodes the mineralocorticoid receptor. PHA1b is an autosomal recessive disorder caused by defects in the 3 epithelial sodium channel subunits" — PMID: 41905953

"Aldosterone is synthesized in the adrenal zona glomerulosa via the action of the mitochondrial cytochrome P450 enzyme aldosterone synthase (CYP11B2) through sequential enzyme reactions." — PMID: 41229259

Finding 5 — Epidemiology and founder mutations (Jews of Iranian origin, ~1/4,000)

CMO II deficiency is relatively frequent among Jews of Iranian origin, with an estimated incidence of 1 in 4,000 births. Affected individuals are homozygous for two CYP11B2 missense variants, p.R181W and p.V386A, inherited together on a founder haplotype. Functional expression showed that R181W reduces 18-hydroxylase and abolishes 18-oxidase activity while leaving 11β-hydroxylase intact, whereas V386A causes a small reduction in 18-hydroxycorticosterone production. Critically, individuals homozygous for R181W alone (n=8) or V386A alone (n=3) were asymptomatic, demonstrating that the two variants act additively to produce disease. Globally the disorder is ultra-rare; most other reports are single consanguineous kindreds, consistent with autosomal recessive inheritance.

"CMO-II deficiency is frequent among Jews from Iran (1 in 4000 births)" — PMID: 8481357

"two candidate mutations, R181W and V386A, were found in the CYP11B2 genes" — PMID: 1594605

"R181W reduced 18-hydroxylase and abolished 18-oxidase activities but left 11 beta-hydroxylase activity intact, whereas V386A caused a small but consistent reduction in the production of 18-hydroxycorticosterone" — PMID: 1594605

"All individuals affected with CMO-II deficiency were homozygous for both mutations, whereas eight asymptomatic subjects were homozygous for R181W alone and three were homozygous for V386A alone" — PMID: 1594605

Finding 6 — Enzyme biochemistry: a three-step mitochondrial P450 reaction

Aldosterone synthase (CYP11B2, UniProt P19099) is a mitochondrial cytochrome P450 that converts 11-deoxycorticosterone to aldosterone via three sequential reactions: 11β-hydroxylation (→ corticosterone), 18-hydroxylation (→ 18-hydroxycorticosterone), and 18-oxidation (→ aldosterone). The enzyme coordinates its substrate at a catalytic heme moiety in the substrate-binding pocket (demonstrated structurally with the inhibitor dexfadrostat). Disease variants are characterized functionally in heterologous expression systems (cultured mammalian cells; fission yeast Schizosaccharomyces pombe) by measuring residual 11β-/18-hydroxylase and 18-oxidase activity. CMO I variants abolish all terminal activity (no aldosterone, low 18-OHB), whereas CMO II variants retain 18-hydroxylase but lose 18-oxidase (normal/low aldosterone, high 18-OHB).

"The aldosterone synthase, CYP11B2, catalyses the conversion of 11-deoxycorticosterone to aldosterone, a process that requires three steps: a hydroxylation at position 11β to form corticosterone, another one at position 18 to produce 18-hydroxycorticosterone, and, finally, an oxidation at position 18 to form aldosterone." — PMID: 21237269

"precisely coordinates with the catalytic heme moiety in the space of the CYP11B2 substrate binding pocket forming a tight and stable complex" — PMID: 37827219

"the heterologous expression of the mutants of CYP11B2 in fission yeast (Schizosaccharomyces pombe) followed by steroid bioconversion assays for the enzymatic characterisation of the investigated mutants" — PMID: 21237269

Relevant CHEBI entities: aldosterone (CHEBI:27584), corticosterone (CHEBI:16827), 11-deoxycorticosterone (CHEBI:16973), 18-hydroxycorticosterone, potassium(1+) (CHEBI:29103), sodium(1+) (CHEBI:29101).

Finding 7 — Natural history and prognosis (multicenter cohort data)

A multicenter cohort of 16 patients from 12 families (8 female) quantified the natural history: median age at presentation 3.1 months (range 0.4–8.1), with poor weight gain the most common presenting symptom (56.3%). Median age at starting fludrocortisone was 3.6 months, and catch-up growth was achieved a median of 2 months after treatment began. Fludrocortisone was successfully discontinued in 5/16 patients at a median age of 6.0 years (range 2.2–7.6). Importantly, reduced aldosterone synthase activity persisted biochemically even after discontinuation, confirming that clinical remission reflects compensatory maturation (increasing dietary salt, maturing renal mineralocorticoid sensitivity) rather than resolution of the enzyme defect.

"Catch-up growth was achieved at median 2 months (range: 0.5 to 14.5) after treatment. Fludrocortisone could be stopped in 5 patients at a median age of 6.0 years (range: 2.2 to 7.6)." — PMID: 34415991

"Sixteen patients from 12 families were included (8 females; median age at presentation: 3.1 months, range: 0.4 to 8.1). The most common symptom was poor weight gain (56.3%)." — PMID: 34415991

"Plasma steroid profiles revealed reduced aldosterone synthase activity both at diagnosis and after discontinuation of treatment compared to age-matched controls." — PMID: 34415991

Finding 8 — Variant spectrum and the CYP11B1 homology pitfall

Pathogenic CYP11B2 variants span all molecular classes and are enriched in consanguineous populations: missense (p.T185I — most common at 40% in a Turkish cohort; also p.Y195H, p.F130L, p.G452W, p.G288S, p.G452R, p.R181W, p.V386A, p.E198D), nonsense (p.Q338stop), frameshift (p.Ser344Profs9), splice-site (c.1200+1G>A, c.1122-18G>A), and in-frame deletions (p.E198del, p.I339_E343del, p.K175del, deletion of Arg173). Novel variants continue to be reported in Palestinian, Turkish, Arab, Chinese, Indian, and Polish patients from consanguineous or founder backgrounds. Variants are germline, biallelic (homozygous or compound heterozygous), and loss-of-function, classified pathogenic/likely pathogenic under ACMG criteria with functional/structural support. A key diagnostic caveat: CYP11B2 shares ~95% sequence identity with the neighboring CYP11B1 gene*, creating sequencing pitfalls and risk of chimeric/unequal-crossover alleles.

"We identified 6 novel (p.Y195H, c.1200 + 1G > A, p.F130L, p.E198del, c.1122-18G > A, p.I339_E343del) and 4 previously described CYP11B2 variants. The most common variant (40%) was p.T185I." — PMID: 34415991

"revealed three homozygous pathogenic variants: p.Ser344Profs9, p.G452W in two patients from an extended family, and p.Q338stop"* — PMID: 33438832

"describe potential pitfalls in CYP11B2 sequencing due to its homology to CYP11B1" — PMID: 39700478

Finding 9 — Formal diagnostic criteria separate ASD from PHA1 and CAH

A consensus diagnostic framework (Japanese Intractable Adrenal Disorders Research) defines ASD by: (clinical) salt-wasting symptoms — poor feeding, vomiting, dehydration, poor weight gain — AND absence of skin pigmentation; plus (laboratory) low serum sodium with high serum potassium; low-to-normal plasma aldosterone with high plasma renin activity/active renin concentration; and no low blood cortisol. Diagnoses of exclusion include PHA1 and 21-hydroxylase deficiency. This operationalizes the key discriminators: aldosterone is LOW/normal in ASD (deficiency) vs HIGH in PHA1 (resistance); cortisol is normal in ASD vs low in salt-wasting CAH; and there is no hyperpigmentation.

"1) Presents with salt-wasting symptoms (poor feeding, vomiting, dehydration, poor weight gain). 2) No skin pigmentation." — PMID: 41905953

"2) Low to normal plasma aldosterone and high plasma renin activity or high plasma active renin concentration. 3) No low blood cortisol level." — PMID: 41905953

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. A biallelic loss-of-function CYP11B2 mutation (germline, homozygous or compound heterozygous) leads to deficient or absent aldosterone synthase protein/activity in the adrenal zona glomerulosa.
2. Deficient aldosterone synthase activity results in failure of the terminal reactions of aldosterone biosynthesis — specifically 18-hydroxylation and/or 18-oxidation of corticosterone.
3. This leads to profound aldosterone deficiency (CMO I: no aldosterone; CMO II: low/inappropriately normal aldosterone with accumulated 18-hydroxycorticosterone — hence the diagnostic high 18-OHB/aldosterone ratio).
4. Loss of circulating aldosterone results in loss of mineralocorticoid-receptor–driven ENaC and Na⁺/K⁺ transport in the aldosterone-sensitive distal nephron (inferred from the known physiology of MR/ENaC signaling).
5. Impaired distal sodium reabsorption and potassium/H⁺ secretion lead to renal sodium wasting with impaired potassium and acid excretion.
6. This results in hyponatremia, hyperkalemia, metabolic acidosis, and hypovolemia.
7. Hypovolemia and hyponatremia lead to compensatory activation of the renin–angiotensin system (hyperreninemia), which cannot be translated into aldosterone because the enzymatic block is downstream.
8. The net effect results in a neonatal/infantile salt-wasting crisis with dehydration, vomiting, and failure to thrive — potentially lethal if untreated.

Branch point (preserved pathway): Because the lesion is specific to the terminal zona-glomerulosa enzyme, cortisol and sex-steroid synthesis are unaffected. This branch explains the two defining clinical negatives — normal cortisol and no hyperpigmentation — which separate ASD from salt-wasting CAH and from primary adrenal insufficiency.

Age-dependent amelioration branch: Over time, increasing dietary salt intake and maturing renal tubular mineralocorticoid sensitivity compensate for the persistent enzyme deficit, allowing clinical (but not biochemical) remission and discontinuation of therapy by mid-childhood.

Compact pathway diagram

CYP11B2 biallelic LOF mutation
│
▼
↓ Aldosterone synthase activity (zona glomerulosa mitochondria)
│
▼
Block of 18-hydroxylation / 18-oxidation of corticosterone
│
├── CMO I  → no aldosterone, low/normal 18-OHB
└── CMO II → low/normal aldosterone, HIGH 18-OHB  ⇒ ↑18-OHB/aldo ratio
│
▼
Aldosterone deficiency        ╌╌╌╌╌  Cortisol/sex steroids PRESERVED
│                             (⇒ normal cortisol, NO hyperpigmentation)
▼
↓ MR→ENaC / Na-K transport in distal nephron  (inferred)
│
▼
Renal Na⁺ wasting + impaired K⁺/H⁺ excretion
│
▼
Hyponatremia + Hyperkalemia + Metabolic acidosis + Hypovolemia
│
▼
Compensatory RAAS activation → HIGH renin (aldosterone cannot rise)
│
▼
Salt-wasting crisis, failure to thrive (lethal if untreated)
│
▼
Fludrocortisone ± NaCl → electrolyte correction + catch-up growth
│
▼
Age-dependent amelioration (↑dietary salt, ↑tubular MR sensitivity)
   → therapy often discontinuable by mid-childhood

Ontology term suggestions

Section-by-Section Characterization

1. Disease Information

Isolated aldosterone synthase deficiency (CMO I/II), an autosomal recessive inborn error of adrenal steroidogenesis. Identifiers: MONDO:0035320; OMIM 203400 (CMO I) and 610600 (CMO II); gene CYP11B2 (8q24.3); protein UniProt P19099. Synonyms as listed above. Information derived from aggregated disease-level resources and primary clinical literature.

2. Etiology

Causal factor: purely genetic — biallelic loss-of-function CYP11B2 variants. Genetic risk factors: founder/consanguineous backgrounds dramatically raise risk (e.g., Iranian-Jewish R181W+V386A haplotype). No established environmental causes; the disease is monogenic. Protective/modifier factors: none proven genetically, but dietary salt intake and maturation of renal mineralocorticoid sensitivity act as powerful acquired modifiers of clinical severity with age. Gene–environment interaction: the principal interaction is between the fixed enzymatic deficit and dietary sodium availability — high salt intake offsets renal sodium wasting and underlies age-dependent remission.

3. Phenotypes

Severity: severe in infancy (potentially lethal salt-wasting crises), self-ameliorating with age. Progression: episodic crises early; overall course improves (clinical remission by mid-childhood). Quality of life: major in untreated infancy; excellent with timely treatment and after age-related remission.

4. Genetic / Molecular Information

Causal gene: CYP11B2 (8q24.3). Variant classes: missense, nonsense, frameshift, splice-site, and in-frame deletions — all germline, biallelic, loss-of-function (see Finding 8). Allele frequencies: pathogenic alleles are rare globally but locally common on founder haplotypes (e.g., R181W+V386A in Iranian Jews). Functional consequence: loss of function (reduced/absent 18-hydroxylase and/or 18-oxidase activity). Diagnostic caveat: ~95% homology with CYP11B1 risks mis-mapping and chimeric alleles. No epigenetic or large chromosomal mechanisms are established for this disorder.

5. Environmental Information

No toxic, infectious, or occupational cause. The one environmentally modifiable factor is dietary sodium: low intake unmasks/worsens salt wasting; higher intake (and salt supplementation) mitigates it.

6. Mechanism / Pathophysiology

See the ordered causal chain and diagram above. Upstream: CYP11B2 LOF → zona glomerulosa mitochondrial enzyme failure. Downstream: aldosterone deficiency → distal-nephron sodium wasting → electrolyte derangement → RAAS activation. Preserved branch: intact cortisol/androgen synthesis.

7. Anatomical Structures Affected

• Primary organ: adrenal gland, specifically the adrenal cortex zona glomerulosa (UBERON:0001228), site of the enzymatic defect.
• Secondary (functionally affected) organ: kidney — aldosterone-sensitive distal nephron (distal convoluted tubule, connecting tubule, collecting duct principal cells), where mineralocorticoid action is lost.
• Body system: endocrine (adrenal steroidogenesis) and renal/electrolyte-regulatory.
• Subcellular compartment: mitochondrion (GO:0005739) — aldosterone synthase is a mitochondrial inner-membrane P450.
• Lateralization: bilateral (systemic hormonal deficiency).

8. Temporal Development

Onset: neonatal to early infancy (median presentation ~3.1 months; range 0.4–8.1). Pattern: acute salt-wasting crises on a chronic genetic background. Course: severe early, then progressive clinical amelioration with age. Remission: treatment can be discontinued in a substantial fraction (5/16; median 6.0 years) — a treatment-withdrawable clinical remission despite persistent biochemical deficit. Critical period: infancy is the window of vulnerability (crisis risk) and of therapeutic opportunity.

9. Inheritance and Population

Inheritance: autosomal recessive. Penetrance: essentially complete for biallelic LOF genotypes, though expressivity varies (CMO I vs II; allele-dependent). Epidemiology: ultra-rare globally; ~1/4,000 births among Jews of Iranian origin (founder effect). Founder effect: R181W+V386A compound haplotype. Consanguinity: major driver — most non-founder cases arise in consanguineous Palestinian, Turkish, Arab, Chinese, Indian kindreds. Sex ratio: no strong sex bias (cohort 8/16 female). Carrier frequency: elevated in founder/consanguineous populations; heterozygotes are asymptomatic.

10. Diagnostics

Laboratory: serum electrolytes (↓Na⁺, ↑K⁺, acidosis); plasma renin activity (high); plasma aldosterone (low/inappropriately normal); multisteroid profiling showing elevated DOC, corticosterone, 18-OHDOC, and the pathognomonic high 18-OHB/aldosterone ratio (CMO II); normal cortisol. Genetic testing: CYP11B2 single-gene sequencing or targeted adrenal/steroidogenesis gene panels; WES/WGS for atypical cases — with careful handling of CYP11B1 homology. Clinical criteria: salt-wasting symptoms + no skin pigmentation + the laboratory profile above (Finding 9). Differential diagnosis: PHA1 (high aldosterone, resistance), salt-wasting CAH / 21-hydroxylase deficiency (low cortisol, virilization, hyperpigmentation), secondary PHA (renal/urologic disease, UTI/reflux). Screening: cascade/carrier testing in affected families and founder populations.

11. Outcome / Prognosis

Excellent with early recognition and mineralocorticoid replacement: normal growth and development, catch-up growth within ~2 months. Mortality: untreated infantile salt-wasting crises can be fatal. Morbidity: minimal once treated. Prognostic factors: timeliness of diagnosis and treatment; CMO subtype. Long-term, many patients achieve treatment-free clinical remission while retaining a subclinical enzyme defect.

12. Treatment

Mainstay: fludrocortisone (synthetic mineralocorticoid; NCIT: Fludrocortisone), ± sodium chloride supplementation in infancy. Corrects electrolytes, restores volume, enables catch-up growth. Pharmacogenomics / advanced/gene/cell/RNA therapies: none established or required — the disorder is managed effectively by hormone replacement. Treatment strategy: initiate in infancy, titrate to electrolytes/renin/growth, and attempt supervised discontinuation in mid-childhood once salt tolerance and renal sensitivity mature. Adverse events: standard mineralocorticoid excess risks (hypertension, hypokalemia) if overdosed — monitored by electrolytes and blood pressure.

13. Prevention

No primary prevention (monogenic). Secondary prevention: early detection and prompt fludrocortisone prevent crises and failure to thrive. Genetic counseling / screening: autosomal recessive counseling, carrier and cascade testing in founder/consanguineous families; prenatal/preimplantation options where a familial variant is known. Tertiary prevention: electrolyte monitoring and salt management to prevent recurrent crises.

14. Other Species / Natural Disease

Human disease (NCBI Taxon 9606). Murine models of aldosterone synthase deficiency (aldosterone synthase-deficient mice) are used experimentally to study renal potassium/sodium handling (e.g., tissue-kallikrein and NCC studies). Orthologous gene: mouse Cyp11b2. No prominent naturally occurring companion-animal counterpart is established in the reviewed literature.

15. Model Organisms

Mouse is the principal model: aldosterone synthase (Cyp11b2)-deficient mice recapitulate aldosterone-independent physiology and have been used to dissect distal-nephron potassium handling and renal adaptation (e.g., PMID 20624970 used aldosterone synthase-deficient mice to show aldosterone-independent control of tissue kallikrein). In vitro: heterologous expression in cultured mammalian cells and fission yeast (S. pombe) enables steroid-bioconversion assays to functionally classify CYP11B2 variants (PMID 21237269). Applications: variant functional characterization, steroidogenesis pathway dissection, renal electrolyte physiology. Limitations: rodent adrenal zonation and steroid profiles differ from humans; in vitro systems isolate enzymatic activity but not whole-organism salt handling.

Evidence Base

Supporting/contextual literature also reviewed: PMID 32539318 (CMO II novel mutations), 41426917 (ASD type I novel variant, neonate), 37332400 (CMO1 case reports), 35848593 (novel CYP11B2 variant), 15179565 and 22764468 (differential diagnosis: selective hypoaldosteronism vs PHA1), 38324138 and 38027139 (chimeric CYP11B1/CYP11B2 alleles), 41709876 (rare CAH subtypes including ASD), 6507399 (Iranian-Jewish CMO II child). Several RAAS/renal-physiology and mouse-model papers (e.g., 20624970, 23447069, 20049674) provide mechanistic context for aldosterone action and model-organism applications.

Limitations and Knowledge Gaps

1. Small evidence base. The disorder is ultra-rare; most data come from single kindreds, founder cohorts, and one 16-patient multicenter series. There are no large-scale prevalence, incidence, or outcome datasets outside founder populations.
2. Downstream nephron step is inferred. The loss of MR→ENaC signaling in the distal nephron is drawn from general mineralocorticoid physiology rather than disease-specific tissue studies in ASD patients.
3. Genotype–phenotype relationships are incompletely resolved. The boundary between CMO I and CMO II is biochemical and allele-dependent, and some variants produce intermediate phenotypes; residual-activity thresholds are approximate.
4. Quality-of-life and long-term outcome data are sparse. Formal QoL instruments (EQ-5D, SF-36, PROMIS) have not been applied; long-term adult outcomes after childhood remission are under-characterized.
5. No omics-scale molecular profiling (transcriptomic/proteomic/metabolomic) specific to ASD adrenal tissue was identified; mechanism rests on enzymology and steroid biochemistry.
6. Diagnostic homology pitfall (CYP11B2/CYP11B1 ~95% identity) may cause under- or mis-diagnosis in laboratories not using homology-aware methods.

Proposed Follow-up Experiments / Actions

1. Build an international ASD registry capturing genotype, steroid profiles (including 18-OHB/aldosterone ratio), treatment course, age at discontinuation, and long-term adult outcomes to firm up natural history and penetrance/expressivity.
2. Systematic functional classification of all reported CYP11B2 variants in a standardized assay (e.g., S. pombe or mammalian expression) to produce a quantitative residual-activity ladder predicting CMO I vs II vs intermediate phenotypes.
3. Homology-aware diagnostic protocols (long-read sequencing, MLPA/CNV analysis) to resolve CYP11B1/CYP11B2 chimeras and prevent misclassification; validate against known founder haplotypes.
4. Prospective QoL and growth outcome study using standardized instruments, including after treatment discontinuation, to document remission durability and any late relapse risk.
5. Mechanistic confirmation of the distal-nephron step in patient-derived or model systems (e.g., renal organoids/iPSC-derived tubular cells) to move the MR→ENaC step from inferred to demonstrated.
6. Carrier-screening evaluation in founder/consanguineous populations (Iranian-Jewish, Palestinian, Turkish, Arab cohorts) to quantify carrier frequency and inform genetic counseling and prenatal/preimplantation options.

Report compiled from 9 confirmed findings and 38 reviewed papers over 5 investigation iterations. Evidence types span human clinical case reports/series, in vitro functional expression assays, structural biology, and model-organism studies.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0002902 (2 mentions) - the report calls it "Lab abnormality"; HP calls it Hyponatremia
• HP:0002153 (2 mentions) - the report calls it "Lab abnormality"; HP calls it Hyperkalemia
• HP:0001942 (2 mentions) - the report calls it "Lab abnormality"; HP calls it Metabolic acidosis
• HP:0001508 (2 mentions) - the report calls it "Clinical sign"; HP calls it Failure to thrive
• HP:0001944 (2 mentions) - the report calls it "Clinical sign"; HP calls it Dehydration
• HP:0002013 (2 mentions) - the report calls it "Symptom"; HP calls it Vomiting
• HP:0011046 (2 mentions) - the report calls it "Lab abnormality"; HP calls it Agenesis of primary maxillary central incisor
• HP:0000848 (2 mentions) - the report calls it "Lab abnormality"; HP calls it Increased circulating renin concentration
• UBERON:0001228 (2 mentions) - the report calls it "adrenal cortex zona glomerulosa"; UBERON calls it renal papilla

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• GO:0005739 (2 mentions) - the report calls it "mitochondrion", "Subcellular compartment: mitochondrion"; GO calls it mitochondrion

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• GO:0005739 - called "mitochondrion", "Subcellular compartment: mitochondrion"